enGene Therapeutics Inc. 10-Q — AI Bull & Bear Analysis

The latest 10-Q reveals a company at a crossroads, balancing a massive capital injection against an aggressive operational burn. While the $255.2 million in total liquidity provides a temporary reprieve, the underlying financial health is strained by a $59.4 million cash outflow from operations over the last six months. The company's survival now hinges entirely on the clinical success of detalimogene and its ability to transition from a research-heavy entity to a commercial-stage pharmaceutical company. Ultimately, the filing highlights a high-stakes gamble on the DDX platform. The company has successfully pushed back its immediate bankruptcy risk through debt and equity markets, but it has done so at the cost of significant shareholder dilution and increased leverage. The market's focus now shifts from financial solvency to clinical execution as the company approaches its 2026 BLA submission window.